HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice.

Abstract

Human epidermal growth factor receptor 2 (HER2) testing is required for newly diagnosed breast cancer and advised for recurrent and metastatic breast cancer, to determine treatment planning using HER2-directed therapy in the neoadjuvant, adjuvant and advanced disease settings. Wide variation, nationally, in the turnaround time for HER2 testing may hinder… (More)
DOI: 10.1136/jclinpath-2013-201819

Topics

  • Presentations referencing similar topics